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Abstract
Background: Although being widespread in the hippocampus, the role tachykinins play in synaptic
transmission is unclear. The effect of substance P on field potentials evoked by stimulation of the
Schaffer collateral-commissural fibres and recorded from the CA1 region of the rat hippocampal
slice were studied.
Results: Perfusion of substance P (8 µM) had no effect on the fEPSP or population spike. Substance
P did however cause a selective reduction in the paired pulse depression of population spikes
evoked by paired stimulation at interpulse intervals of 20–80 msec. A comparison of the actions of
other tachykinin receptor agonists gave an order of potency of substance P > [β-Ala8]-neurokinin
A (4–10) > senktide. The effect of substance P was reduced by the neurokinin-1 receptor
antagonist SR140333, but not by the neurokinin-2 or neurokinin-3 receptor antagonists, MDL
29,913 or [Trp7, β-Ala8]-neurokinin A (4–10).
Conclusion: The order of potency of the agonists, and the effects of the antagonists, both indicate
that the effect of substance P on paired pulse depression is mediated by neurokinin-1 receptors.
Background
The mammalian tachykinins are a group of peptides shar-
ing the common C-terminal sequence Phe-X-Gly-Leu-
Met-NH2. The three principal tachykinins are substance P,
neurokinin A and neurokinin B, and although these are
preferred agonists for the neurokinin-1, neurokinin-2 and
neurokinin-3 receptors respectively, they are not com-
pletely selective for any one receptor subtype [1,2]. Tach-
ykinin receptors are distributed throughout the CNS, with
all three receptor subtypes being expressed in the adult rat
hippocampus [3-6]. A dense network of fibres containing
substance P innervates the stratum oriens, stratum radiatum
and alveus of the rat hippocampus. These may arise from
both extrinsic sources such as the septum and hypothala-
mus, and from intrinsic GABA-containing interneurones
[7,8].
Although being widespread in the hippocampus, the role
tachykinins play in normal synaptic transmission is
unclear. Using extracellular recordings from the mouse
hippocampal slice, substance P and its analogue sub-
stance P methyl ester have been reported to cause a
decrease in the amplitude and slope of the field excitatory
postsynaptic potential (fEPSP) recorded from the CA1
stratum pyramidale [9]. The effect was blocked by the selec-
tive neurokinin-1 receptor antagonist SR140333, suggest-
ing the action was NK-1 receptor mediated. The effect of
substance P methyl ester was blocked by bicuculline, an
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antagonist for GABAA receptors, and not by glutamate
receptor antagonists. The authors concluded the depres-
sant effect of substance P and substance P methyl ester
required an intact GABAergic system, with substance P
causing facilitation of GABAergic neurotransmission,
thereby increasing inhibitory synaptic transmission [9].
The aim of this present study was to use extracellular field
recordings to a) identify the effect of substance P on syn-
aptic transmission in the CA1 region of the rat hippocam-
pus, and b) to use selective pharmacological agonists and
antagonists to determine which tachykinin receptors were
involved.
Results
Substance P had no effect on fEPSP's
fEPSPs were recorded from the CA1 region of the rat hip-
pocampus using single pulse stimulation of the Schaffer
collateral commissural fibres at 30 s intervals. Perfusion of
15 µM substance P for 10 min had no significant effect on
the amplitude of the fEPSP (106 ± 5% of control at the
end of drug perfusion, figure 1(a) and 1(b), not signifi-
cant) or the slope of the fEPSP (113 ± 2% of control at the
end of drug perfusion, figure 1(a) and 1(c), not signifi-
cant).
Contrary to previous experiments performed in the mouse
hippocampus [9]), we therefore found no effect of sub-
stance P on fEPSPs recorded in the rat hippocampus.
Existing immunohistochemical and electrophysiological
data point to the fact that substance P receptors are found
solely on inhibitory interneurones in the hippocampus
[8,10]. In our recording conditions, GABAergic transmis-
sion plays a minimal role in determining the slope or
amplitude of the fEPSP. We therefore turned to recording
synaptic responses in which GABAergic transmission
clearly has an effect. Synaptic stimulation of CA1 pyrami-
dal neurones evokes a powerful feedback inhibition,
which is mediated by GABAA receptors [11]. Paired pulse
stimulation can be used to evoke a second response dur-
ing this phase inhibition and the extent of paired pulse
depression can be used as an index of the strength of
GABAergic transmission [12]. We therefore investigated
next the action of substance P on paired pulse depression
of population spikes.
Substance P decreased paired pulse depression
There is some variability in the extent of paired pulse
depression observed between individual slices. In general,
those slices deemed healthy by the criterion of not show-
ing a secondary population spike to a single stimulus, also
show good paired pulse depression. Overall, ie prior to
any selection of slices, when pulses were delivered 20 ms
apart, the mean amplitude of the second population spike
(PS2) was 55 ± 11% of the amplitude of the first (PS1) (n
= 10). For the following experiments however, unless oth-
erwise stated, only those slices in which PS2 was 70% or
less of PS1 when using a 20 ms interpulse interval were
used. Slices were stimulated every 30 s with paired pulses
delivered 20 ms apart. A control period of at least 15 min
was established, in which both PS1 amplitude and extent
of paired pulse depression were stable, and then sub-
stance P was applied. Perfusion of 8 µM substance P for 10
minutes was found to cause an increase in the amplitude
of PS2 while having no effect on PS1 (figure 2(b) and
2(c), n = 7). The mean amplitude of PS2 during the con-
trol period was 37 ± 9% of PS1, and this increased to 88 ±
8% of PS1 (p > 0.05) at the end of drug perfusion. This
increase in PS2 was not accompanied by any significant
Perfusion of substance P (15 µM) had no effect on the ampli- tude or slope of the fEPSP recorded from the CA1 region of  the rat hippocampal slice Figure 1
Perfusion of substance P (15 µM) had no effect on the ampli-
tude or slope of the fEPSP recorded from the CA1 region of 
the rat hippocampal slice. (a) Example synaptic response 
recorded from a single slice using a single stimulus of the 
Schaffer collateral-commissural fibres every 30 s. The 
response on the left was recorded under control conditions 
whereas the trace on the right was recorded in the presence 
of substance P (15 µM). (b) and (c) Pooled time course data 
showing the lack of effect of substance P on the slope (b) and 
amplitude (c) of the fEPSP. Points represent mean ± s.e.m., n 
= 4. Scale bar represents 0.5 mV and 10 ms.BMC Neuroscience 2005, 6:66 http://www.biomedcentral.com/1471-2202/6/66
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effect on the amplitude of PS1, which was 114 ± 8% of
control at the end of drug perfusion (p = 0.1 not signifi-
cant). The peak effect of substance P on paired pulse
depression was observed within 10 min of perfusion, and
the effect was reversible towards control levels over 20–30
min.
In a different set of experiments, we next examined
whether the effect of substance P was limited to those
interpulse intervals that correspond with the time course
Perfusion of substance P (8 µM) had no effect on the ampli- tude of PS1 but reduced paired pulse depression Figure 2
Perfusion of substance P (8 µM) had no effect on the ampli-
tude of PS1 but reduced paired pulse depression. (a) Example 
synaptic response recorded from a single slice using paired 
pulse stimulation at an interstimulus interval of 20 ms. The 
response on the left was recorded under control conditions 
whereas the trace on the right is that recorded in the pres-
ence of substance P (8 µM). (b) Pooled time course data 
showing that perfusion of substance P for 10 min (black bar) 
had no effect on the amplitude of PS1. (c) Pooled time course 
data from the same set of experiments showing PS2 
expressed as a % of PS1. Substance P (8 µM) perfused for 10 
min (black bar) significantly increased PS2 amplitude and 
therefore decreased paired pulse depression. Points repre-
sent mean ± s.e.m., n = 7. (d) The effect of substance P on 
the full range of interstimulus intervals recorded during con-
trol conditions (open bars) and during drug perfusion (filled 
bars). * denotes p < 0.05, ** denotes p > 0.01, n = 9. Scale 
bar represents 1 mV and 10 ms.
The effect of tachykinin receptor agonists on paired pulse  depression Figure 3
The effect of tachykinin receptor agonists on paired pulse 
depression. All agonists were perfused for 10 min. (a) Bars 
represents the control paired pulse depression using an 
interstimulus interval of 20 ms (PS2 amplitude expressed as a 
% of PS1, open bars), compared to that recorded in the pres-
ence of each agonist (filled bars). Substance P methyl ester 
significantly increased the amplitude of PS2, p > 0.05, n = 9. 
(β8Ala) neurokinin A (4–10) and senktide failed to have any 
significant effect on the amplitude of PS2, n = 4 for both. Sub-
stance P significantly increased the amplitude of PS2, p > 
0.05, n = 7. (b) Example synaptic response recorded from 3 
different representative slices. Top row of traces are con-
trols, bottom traces are those recorded during perfusion of 
each tachykinin agonist. Scale bar represents 1 mV and 10 
ms.BMC Neuroscience 2005, 6:66 http://www.biomedcentral.com/1471-2202/6/66
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of GABAergic feedback inhibition. Using paired pulse
stimulation at interpulse intervals of 20, 40, 80 and 150
ms, the effect of 8 µM substance P perfused for 10 min was
studied. The effect of substance P was evident only at the
shorter interpulse intervals of 20–80 ms (figure 2(d), n =
9). The greatest increase in amplitude of PS2 was observed
at the 40 ms interpulse interval where the control ampli-
tude of PS2 was 43 ± 12% of PS1, but increased to 78 ±
12% of PS1 at the end of drug perfusion (p = 0.005). Sub-
stance P also caused a smaller but still significant increase
in the amplitude of PS2 at the 20 ms interpulse interval
(PS2 amplitude increased from 23 ± 7 to 45 ± 13% of PS1,
p = 0.03) and the 80 ms interpulse interval (PS2 ampli-
tude increased from 92 ± 14 to 124 ± 4% of PS1, p = 0.03).
In contrast, substance P had no significant effect at the
150 ms interpulse interval (p = 0.2). Further to this, in the
minority of slices which, even at short interpulse intervals
showed no paired pulse depression, perfusion of 8 µM
substance P had no effect on the amplitude of the first or
second population spike (n = 3, data not shown).
Effect of other tachykinin agonists on paired pulse 
depression
Substance P is most potent at the neurokinin-1 receptor,
however, it can also activate the other tachykinin recep-
tors (neurokinin-2 and neurokinin-3). Establishing an
order of potency of selective agonists in mimicking the
effect of substance P is therefore a useful indicator of
which receptor mediates the effect.
Substance P methyl ester has been reported to be a potent
neurokinin-1 receptor agonist [13]. Using paired pulse
stimulation with an interpulse interval of 20 ms, per-
fusion of 0.5 µM substance P methyl ester for 10 min had
no effect on PS1, but significantly increased the amplitude
of PS2, though the effect appeared smaller than that pro-
duced by 8 µM substance P. Substance P methyl ester pro-
duced an increase in PS2 amplitude from 21 ± 7% to 39 ±
10% of PS1 at the end of drug perfusion (p < 0.05, figure
3, n = 8), while having no effect on PS1 (PS1 amplitude
was 114 ± 9% of control at the end of drug perfusion).
[β8Ala]-neurokinin A (4–10) is an neurokinin-2 receptor
preferring agonist [14]. Using paired pulse stimulation
with an interpulse interval of 20 ms, perfusion of 10 µM
[β8Ala]-neurokinin A (4–10) for 10 min had a small and
statistically insignificant effect on PS2. PS2 amplitude
increased from 31 ± 13% to 51 ± 13% of PS1 at the end of
drug perfusion (not significant, figure 3, n = 4). It too had
no effect on PS1 (amplitude of PS1 was 99 ± 9% of control
at the end of drug perfusion). In order to directly compare
the effect of substance P in the same slices, after a 30-min
washout, 8 µM substance P was perfused for 10 min. This
increased the amplitude of PS2 from 34 ± 4% to 67 ± 30%
of PS1 (data not shown).
Senktide is a neurokinin-3 receptor preferring agonist [15]
and was found to have no effect on the amplitude of PS1
or PS2. Using paired pulse stimulation with an interpulse
interval of 20 ms, 10 µM senktide perfused for 10 min had
The effect of tachykinin receptor antagonists, when perfused  with substance P Figure 4
The effect of tachykinin receptor antagonists, when perfused 
with substance P. (a) Pooled data showing for each antago-
nist; control paired pulse depression using an interstimulus 
interval of 20 ms (PS2 amplitude expressed as a % of PS1, 
open bars), the effect of 8 µM substance P (filled bars), the 
effect of antagonist alone (diagonally hatched bars) and the 
effect of substance P in the presence of SR140333, 
MDL29,913 or [Trp7, β-Ala8]-neurokinin A (4–10) (horizon-
tally hatched bars). The neurokinin-1 receptor antagonist 
SR140333 (12 µM) significantly reduced the effect of sub-
stance P. * denotes P > 0.05, n = 6. The neurokinin-2 recep-
tor antagonist MDl29,913 (12 µM, n = 4) and the NK-3 
antagonist [Trp7, β-Ala8]-neurokinin A (4–10) (5 µM, n = 3), 
had no significant effecton the action of substance P (b) 
Example synaptic response recorded from 3 representative 
slices showing control responses (top row), responses 
recorded in the presence of substance P (middle row), and 
responses recorded in the presence of substance P and the 
antagonist (bottom row). Scale bar represents 1 mV and 10 
ms.BMC Neuroscience 2005, 6:66 http://www.biomedcentral.com/1471-2202/6/66
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no significant effect on the amplitude of PS2 (control
amplitude of PS2 was 33 ± 8% of PS1 compared to 43 ±
5% of PS1 at the end of drug perfusion, not significant, n
= 4, figure 3). In the same slices, after a 30-min washout,
8 µM substance P was perfused for 10 min and it again
increased PS2 amplitude from 33 ± 7% of PS1 to 60 ± 5%
of PS1 at the end of drug perfusion (p < 0.05, data not
shown).
Effect of neurokinin-1, neurokinin-2 and neurokinin-3 
receptor antagonists on the action of substance P
To further characterise the receptor via which substance P
decreased paired pulse depression, we next used three
selective antagonists.
SR140333, a non-peptide neurokinin-1 preferring antago-
nist, was obtained from Sanofi research [16]. To establish
a within-slice control, 8 µM substance P was first perfused
for 10 min and, using an interpulse interval of 20 ms, this
again caused an increase in the amplitude of PS2, as pre-
viously seen. After a 30-min washout period, during
which PPD returned to control levels, 12 µM SR140333
was perfused for 20 min prior to, and during, a second
perfusion of substance P. SR140333 had no effect on
either PS1 or PS2 when perfused alone. However, when 8
µM substance P was perfused in the presence of
SR140333, the effect of substance P on PS2 was reduced
(figure 4). Substance P increased the amplitude of PS2
from 21 ± 8% of PS1 to 75 ± 19% of PS1, and when
applied in the presence of SR140333 it increased PS2 from
19 ± 8% of PS1 to 54 ± 17% of PS1 (n = 6, p > 0.05).
MDL 29,913 is a neurokinin-2 receptor antagonist [17].
Using the same protocol as described above, the effect of
8 µM substance P was established and allowed to recover,
before 5 µM MDL29,913 was applied for 20 min prior to,
and during, a second perfusion of substance P. MDL
29,913 was found to have no effect itself on PS1 or PS2,
or to block the effect of substance P. Substance P perfused
for 10 min caused an increase in PS2 from a control
amplitude of 13 ± 8 of PS1 to 73 ± 26 of PS1 at the end of
drug perfusion. When applied in the presence of MDL
29,913, substance P still increased the amplitude of PS2 to
76 ± 13 of PS1 (n = 4, figure 4).
[Trp7,  β-Ala8]-neurokinin A (4–10) is a neurokinin-3
receptor-preferring antagonist [18]. Using the same proto-
col as described above, 5 µM [Trp7, β-Ala8]-neurokinin A
(4–10) was applied for 20 min prior to, and for 10 min
during, application of substance P. [Trp7, β-Ala8]-neurok-
inin A (4–10) was found to have no effect itself on PS1 or
PS2, or to block the effect of substance P. Within slice con-
trols showed that 8 µM substance P perfused for 10 min
caused an increase in PS2 from a control value of 26 ±
13% of PS1 to 86 ± 3% of PS1 at the end of drug perfusion
(n = 3, figure 4). When 8 µM substance P was perfused in
the presence of 5 µM [Trp7, β-Ala8]-neurokinin A (4–10),
substance P increased the amplitude of PS2 to 76 ± 2% of
PS1.
Discussion
Substance P selectively decreases paired pulse depression
The most striking feature of our results is the selective
effect of substance P on PS2, but not PS1. Tachykinin
receptors are located on inhibitory interneurones and not
pyramidal cells [8] and neurokinin-1 receptors in particu-
lar are located on the cell body and dendrites of GABA
immunopositive interneurones [3]. The location of the
neurokinin-1 receptors would suggest an involvement of
substance P in the control of inhibition of pyramidal neu-
rones, and maybe of other interneurones, but not in
directly modulating excitatory transmission. This is con-
sistent with the fact that substance P had no effect on the
recorded fEPSP or on PS1, which are primarily mediated
by AMPA receptors. This result is, however, in disagree-
ment with previous work. Kouznetsova and Nistri [9]
found that perfusion of substance P (2–4 µM) and its syn-
thetic analogue, substance P methyl-ester, significantly
depressed field potentials recorded from the CA1 region
of the mouse hippocampus. The reason for this discrep-
ancy may be due to species difference (mouse vs. rat), or
alternatively to the baseline recording conditions, and
specifically the level of GABAergic inhibition. Kouznets-
ova and Nistri [9] hypothesised that substance P exerted
its depressant action via GABA interneurones and not
directly on the pyramidal cells recorded from. In our
experiments, we deliberately selected hippocampal slices
that exhibited good paired pulse depression, and there-
fore robust GABAergic inhibition. If this inhibition was
effectively maximal, then substance P may be unable to
further enhance it. It is therefore significant that we have
previously noted paired pulse depression (and therefore
presumably GABAergic transmission) is much weaker in
slices maintained in a submersion chamber of the type
used by Kouznetsova and Nistri, than an interface cham-
ber as used in our experiments.
Since we could not demonstrate any effect of substance P
on synaptic responses to single pulse stimulation, we
turned to the phenomenon of paired pulse depression.
Using an interstimulus interval of 20 ms, substance P (8
µM) perfused onto slices that displayed paired pulse
depression, increased the amplitude of PS2 with no effect
on PS1. Paired pulse depression of population spikes is
thought to be predominately caused by feedback inhibi-
tion and can be used as an index of the strength of
GABAergic neurotransmission within the hippocampus
[12]. As previously noted, neurokinin-1 receptors are
located on interneurones of the hippocampus, and sub-
stance P acting at these receptors could regulate the releaseBMC Neuroscience 2005, 6:66 http://www.biomedcentral.com/1471-2202/6/66
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of GABA. A decrease in GABA release would decrease the
amplitude of the GABAergic IPSP evoked in the pyramidal
neurone, increasing the probability that a second stimulus
would fire an action potential, thereby increasing PS2 and
inhibiting paired pulse depression. This effect was found
to occur only at shorter interstimlus intervals of below 80
ms, which corresponds with the time course of the intrac-
ellularly recorded GABAA receptor mediated IPSP evoked
in the CA1 pyramidal neurones [19]. An effect on inhibi-
tory synaptic transmission is supported by the anatomical
localisation of substance P receptors to GABA-containing
interneurones and not to glutamate containing principal
(pyramidal) cells [7]. Furthermore, electrophysiological
recordings show that neurokinin-1 receptor agonists
depolarise interneurones and increase the frequency of
spontaneous (action potential dependent) inhibitory post
synaptic currents (IPSCs) recorded from pyramidal cells
in the CA1 region of the hippocampus [10]. Whilst these
experiments showed an increase, rather than a decrease in
the frequency of spontaneous IPSCs, they did not investi-
gate the effect of substance P on evoked IPSCs.
Effects of selective tachykinin receptor agonists and 
antagonists
A range of selective tachykinin receptor agonists was
investigated. The neurokinin-1 receptor agonist substance
P methyl ester was selected because it had been previously
found to effectively mimic the effects of substance P in the
mouse hippocampus, where it was effective in a concen-
tration range of 10 nM–5 µM, with the maximum depres-
sant action on field potentials observed using 0.1 µM [9].
In our experiments, perfusion of substance P methyl ester
(0.5 µM), mimicked the effect of substance P and caused
a significant increase in the amplitude of PS2. Due to the
different concentrations used (8 µM and 0.5 µM), it is not
possible to comment on the relative potencies of sub-
stance P and substance P methyl ester in our experiments.
[β-Ala8]-neurokinin A (4–10) has been found to be a
highly selective neurokinin-2 receptor agonist which has a
100-fold higher potency for neurokinin-2 receptors than
for neurokinin-1 receptors [14]. 10 µM [β-Ala8]-neuroki-
nin A (4–10) had a small effect on the amplitude of PS2
although this was not statistically significant. Any effect of
[β-Ala8]-neurokinin A (4–10) on PS2 may be mediated
via neurokinin-2 receptors, or more plausibly, [β-Ala8]-
neurokinin A (4–10) may have some effect on neuroki-
nin-1 receptors [20,21]. Such a weak interaction of neuro-
kinin-2 receptor agonists with neurokinin-1 receptors has
been reported in the entorhinal cortex, where [β-Ala8]-
neurokinin A (4–10) mimicked the action of substance P
in increasing GABA release from interneurones; an effect
which was blocked by a neurokinin-1 receptor antagonist
[10]. The neurokinin-3 receptor agonist senktide is one of
the most potent of the neurokinin-3 receptor agonists
[22]. Perfusion of 10 µM senktide had no effect on the
amplitude of PS2, suggesting that the neurokinin-3 recep-
tor is not involved in the decrease observed in paired
pulse depression and has no effect on synaptic transmis-
sion measured here. A comparison of the effects of the
agonists used gives an order of potency of substance P >
[β-Ala8]-neurokinin A (4–10) > senktide. This is consist-
ent with the effect of substance P on paired pulse depres-
sion being mediated by the neurokinin-1 receptor.
To further characterise the receptor involved, three tachy-
kinin antagonist were used in an attempt to block the
action of substance P. The selective neurokinin-1 receptor
antagonist SR140333 (12 µM) significantly blocked the
effect of substance P, although not completely. In the
guinea pig ileum it was found that for SR140333 to have
its full activity, a long contact time with the tissue was
required [16] and this has been suggested to be longer
than 120 min [23]. Contact time in the experiments per-
formed here was a total of 30 min so an even better block
may have been achieved with a longer perfusion time.
Nevertheless, the ability of SR140333 to reduce the effect
of substance P on paired pulse depression is consistent
with the effect being neurokinin-1 receptor mediated.
This is further supported with complete lack of effect of
the neurokinin-2 receptor antagonist MDL29,913, and
the neurokinin-3 receptor antagonist [Trp7, β-Ala8]-neu-
rokinin A (4–10). An internal control was used in these
experiments, which involved substance being applied
twice to the same slice, firstly in the absence, and then in
the presence of the antagonist. Under these conditions,
desensitization of receptors might be expected to result in
a smaller second response, independent of any antagonist
effects. However, the fact that repeated perfusion of sub-
stance in the presence of the NK2 and NK3 antagonists
produced substantially the same effect suggest that this is
not the case, and that the reduced effect of substance P in
the presence of SR140333 is due to antagonism of neuro-
kinin-1 receptors.
The resulting order of potency of the agonists, and the
effectiveness of the antagonists, therefore both suggest
that the effect of substance P on paired pulse depression is
mediated by neurokinin-1 receptors.
Future work
Whilst the results of our experiments are consistent with
the action of substance P being mediated by neurokinin-
1 receptors, a more definitive proof of this would be to
perform similar experiments in neurokinin-1 receptor
knockout mice to establish whether substance P still
inhibits paired pulse depression in these animals. There is
some evidence that central tachykinin receptors may have
different properties to the better characterised peripheral
tachykinin receptors, and the possibility remains that theBMC Neuroscience 2005, 6:66 http://www.biomedcentral.com/1471-2202/6/66
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central effects of substance P are mediated by a distinct
gene product, albeit with similar properties.
The effect of substance P in selectively decreasing paired
pulse depression is consistent with a decrease in GABAer-
gic inhibitory feedback inhibition of CA1 pyramidal cells,
and such a mechanism is supported by the anatomical
localisation of neurokinin-1 receptors in the hippocam-
pus. However, other factors also contribute to paired
pulse depression [24] and therefore, to investigate this
hypothesis further, future experiments should use intrac-
ellular or whole-cell patch recordings from both pyrami-
dal cells, and from interneurones in the CA1 region.
Whilst there is convincing evidence that substance P
inhibits spontaneous GABA release from interneurones
[10], the effect of substance P on evoked IPSPs has not
been determined. Such experiments will give further
insights into the role of substance P in the central nervous
system.
Conclusion
The results show that perfusion substance P causes a selec-
tive reduction in paired pulse inhibition of population
spikes evoked in the CA1 region of the rat hippocampal
slice, and that this effect is mediated by NK1 receptors.
This is consistent with the notion that NK1 receptors are
present on the terminals of inhibitory interneurones and
act to regulate GABA release.
Methods
Slice preparation
Young adult female Sprague Dawley rats (aged 4–6
weeks) were deeply anaesthetised using halothane and
the brain removed and placed in chilled (4–5°C) oxygen-
ated artificial cerebrospinal fluid (aCSF). The aCSF con-
tained (in mM): NaCl 124, KCl 3, NaHCO3 26, NaH2PO4
1.25, D-glucose 10, MgSO4 1 and CaCl2 2 and was contin-
uously bubbled with 95%O2/5% CO2. After dissecting
free the hippocampus, 400 µm transverse slices were cut
using a McIlwain tissue chopper. Slices were stored in a
holding chamber at room temperature before being trans-
ferred to an interface type-recording chamber. Within the
interface chamber, aCSF was continually perfused below
the slice at a rate of 1–2 ml/min and at a constant temper-
ature of 27–29°C.
Extracellular recordings
Extracellular field recordings were obtained from the CA1
region using a glass recording electrode filled with 3 M
NaCl. The recording electrode was placed in stratum
pyramidale for recording population spikes, or in stratum
radiatum for fEPSP measurements. Population spikes and
fEPSPs were evoked by a bipolar silver stimulating elec-
trode placed in stratum radiatum towards the CA3 end of
the CA1 region to stimulate the Schaffer collateral com-
missural fibres. Constant current stimulus pulses of 0.02
msec width and 2–11 V were set to elicit a response of
approximately half-maximal amplitude. Paired pulse
stimulation at interpulse intervals between 20 and 150 ms
were used in order to identify effects on both the first pop-
ulation spike (PS1), and the extent of paired pulse depres-
sion of the second population spike (PS2). Synaptic
responses were evoked every 30 s and collected and ana-
lysed using the LTP program [25].
Drugs and data analysis
All drugs were first dissolved in either water or dimethyl-
sulphoxide (DSMO) according to the suppliers instruc-
tions (see below) to make a stock solution of at least 1000
times the final concentration. All stock solutions were
kept frozen until needed. Application of drugs was
achieved by dilution of stock solution into the aCSF,
which was perfused onto the slice for the required time.
Substance P and MDL 29,913 were obtained from Tocris
(UK); substance P methyl-ester, [β-Ala8]-neurokinin A (4–
10), senktide, spantide II and [Trp7, β-Ala8]-neurokinin A
(4–10) were obtained from Bachem (UK); WIN 51708
was obtained from RBI Sigma (UK). SR140333 was a gift
from Dr X. Emonds-Alt (Sanofi Research, Montpelier,
France). Stock solutions of substance P, substance P
methyl-ester, senktide and MDL 29,913 were all made up
in water, whereas spantide II, [β-Ala8]-neurokinin A (4–
10), [Trp7, β-Ala8]-neurokinin A (4–10), SR140333 and
WIN 51708 were made up in DMSO. To facilitate pooling
of data, fEPSP slopes or population spike amplitudes were
normalised and expressed as a percentage of the mean
slope or amplitude recorded during the entire 15 min con-
trol period before addition of drugs. In experiments using
paired pulse stimulation, the extent of paired pulse
depression was determined by expressing the amplitude
of PS1 as a percentage of the amplitude of PS2. All graphs
represent pooled data from 3–9 slices prepared from dif-
ferent animals and plot the mean ± standard error of the
mean (s.e.m.). Statistical analysis of the raw (ie not nor-
malised) data involved the use of a Students paired t-test
to compare control fEPSP slope, population spike ampli-
tude, or extent of paired pulse depression with that
recorded at the end of drug perfusion. The control
response was measured from the average of the last 5 con-
secutive responses before drug perfusion, and the drug
response was measured from the average of the last 5 con-
secutive responses during drug perfusion. p < 0.05 was
taken as significant.
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